The PI3K-PDK1 signaling pathway has been implicated in mediating resistance to CDK4/6 inhibitors, with ribociclib-resistant breast cancer cell lines demonstrating an increase in PDK1 levels following drug exposure, resulting in activation of the AKT pathway [179]. Here, CDK4 is linked to breast carcinoma.